Introduction
The latest World Health Organization (WHO) figures (June 17, 2009) show that 88 countries have officially reported 39,620 cases of influenza A (H1N1) infection, including 167 deaths. 1 The rapid worldwide spread and the apparent lack of preexisting immunity in humans qualify this as a pandemic virus. The identification of this novel virus in the beginning of April 2009 and subsequent international screening programs have demonstrated that the virus is able to spread from human to human. These data are sufficient to state that we are currently experiencing an influenza pandemic. WHO raised the pandemic influenza alert to phase 6 on June 10, 2009.
H1N1 Virus
The last influenza pandemic was in 1968; H1N1 is therefore the first opportunity to study a pandemic outbreak in real time with all the modern analytical methods that have been developed in recent decades. Indeed, data have been generated with astonishing rapidity. Full-length viral genome sequences from around the world have been published in public-access databases. The internet has been extensively used to keep track of the spread of the virus. Large community efforts have been made to restrict the spread of the virus right from the start of the pandemic. In this issue of the Journal of the Formosan Medical Association, Chang et al present one of the first reviews about this novel virus. 2 The 2009 H1N1 virus is currently presenting itself as a relatively mild form of influenza, with common symptoms such as cough, sore throat, and headache. A characteristic of the 2009 H1N1 infection is the frequent occurrence of diarrhea and vomiting, which is unusual for seasonal influenza. Also, present data seem to show that younger people are more susceptible to infection. However, more data are needed to determine the cause of this, as it may very well be the result of a bias in sampling or a bias in the spread of the virus among the human population. An initial study reported that hospitalization was needed in almost 10% of cases, and the mortality rate was about 0.4%. 3 Based on the officially reported cases, the current mortality rate is approximately 0.4%. Because of the mild pathogenicity, most infected persons will not be reported, and therefore these numbers are certainly a huge overestimation. One possible exception, reported by WHO on June 10, 2009, is that the infection might be more severe in some isolated groups of the Inuit population in Canada. Obviously, more surveys and further analysis are needed to determine the underlying mechanisms. it is likely that the virus has been in pigs for several years. Fortunately, the current spread in humans has been detected relatively early, indicating that the surveillance of the human population is adequate to pick up pandemic influenza.
Surprising Sequence Data
Another surprise from the sequence data is that the virus seems unusually stable in terms of genome evolution. 3, 6 In the context of vaccine development, this is obviously good news. The currently produced vaccines are based on the original viruses and are therefore more likely to be effective. However, it is not clear what this means for the virus-host interaction. It is still possible that this is merely a founder effect. Similar viral sequences from around the world do not mean a lot if it requires only one airplane to transport the virus to another location. But, if this lack of viral evolution remains during the pandemic, then there is apparently little selection pressure on the H1N1 virus to change. This may be related to the limited preexisting immunity. People are infected by this virus, and before the host can mount an appropriate immune response, the virus has propagated sufficiently to reach high enough viral loads to facilitate transmission and spreading in the population. This is in contrast to seasonal influenza, which needs to escape from preexisting immunity in the host. In this respect, it is interesting that the virus has truncated versions of PB1-F2 and NS1 (see the review of Chang et al 2 for more details). These two proteins are associated with high virulence because of their suppressive effect on the host immune system. The PB1-F2 protein has been shown to specifically target and destroy alveolar macrophages (reviewed by Coleman ). The new 2009 influenza A (H1N1) virus is already resistant to adamantine and a novel reassortment virus could be multidrugresistant.
In conclusion, we are currently in a phase 6 pandemic with a novel, relatively mild influenza virus (H1N1). Although we have not been able to stop this pandemic, worldwide efforts have resulted in the rapid identification and characterization of the virus. Continual monitoring and surveillance of the H1N1 virus is required to enable us to respond to any change in the virus that could influence its pathogenicity, resistance to antiviral drugs, or sensitivity to the vaccines that are currently being developed.
